What We're Reading: Page 241
Industry reads hand-picked by our editors
Jan 18, 2019
Jan 17, 2019
Jan 16, 2019
Jan 15, 2019
-
Vantage
Why Novo Nordisk should buy Amarin
-
BioCentury
Amid Onpattro launch, Alnylam raises $387.5M
-
The Wall Street Journal
In Fast-Aging Japan, Elder Care Is a High-Tech Pursuit
-
The Wall Street Journal
Walmart Expected to Leave CVS Caremark Pharmacy Networks Amid Dispute
Jan 14, 2019
-
Reuters
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
-
The Wall Street Journal
Samsung Faces Resistance From Big Pharma in the U.S.
-
Life Sci VC
The Game Isn't Worth The Candle: Reflections on the JPM Healthcare Conference
-
The Washington Post
What happened when biotech startup pursued a new treatment for pancreatic cancer.
Jan 11, 2019
-
Bloomberg
Ex-Banker Walks Into a Conference, Walks Out With $480 Million
-
The Washington Post
'Marketers are having a field day': Patients stuck in corporate fight against generic drugs
-
BioCentury
Patent reform back on agenda in China
-
The Inquirer
Her insurer's price tool estimated less than $1,375 for a breast MRI. Then she got a bill for $3,200.
Previous
